NCT07552428Not yet recruiting
Cognitive Musical Screening and Therapeutic Innovation in Multiple Sclerosis
Neurocognitive Musical Screening and Therapeutic Innovation: A Crossover Randomized Controlled Pilot Study
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
This pilot study evaluates the effectiveness of screening and improving cognitive function in patients with multiple sclerosis (MS) using a musical tool, the Ipsilon. The Ipsilon performance will be compared with established neuropsychological assessments, including the Minimal Assessment of Cognitive Function in MS (MACFIMS) and the Processing Speed Test (PST). Thirty-two participants will be enrolled in a crossover design: half will complete the Ipsilon musical test for 15 minutes daily for seven consecutive days, while the other half will begin with no intervention before switching sequences. Participants will undergo screening for depression, colorblindness, musical background, and upper extremity function. Primary outcomes include evaluating whether the Ipsilon more reliably predicts cognitive domains measured by MACFIMS than the PST and assessing its potential to improve cognitive function. Secondary outcomes will examine associations with work functioning and quality of life.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 32 (estimated)
- First submitted
- 13 Apr 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 1 Oct 2028
- Lead sponsor
- Hunter College of City University of New York
- Diseases
- Multiple sclerosis
- NCT number
- NCT07552428
What you commit to
- Study type: Observational
- Planned participants: 32
- From 1 Oct 2026 to the primary completion date, 1 Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- On psychoactive medications or medications that may influence cognition (e.g. Aricept, Adderall) or active substance abuse
Other illness
- Mental incapacity/major depression or psychiatric illness as determined by the neurology team and a score ≥11 on the Patient Health Questionnaire-9 (PHQ9)
- Neurological conditions (other than MS) or medical illnesses that affect cognitive function (i.e., Alzheimer's disease, stroke)
Age
- Professional musician (≥2 years formal training in last 5 years or ≥ 2 hours/week of currently playing a musical instrument)
Other
- Severe vision/hearing impairments precluding assessments: color blindness, considering the diverse colors featured on the Ipsilon tool.
Who the study is looking for
- diagnosed with multip\[le sclerosis (MS)
- aged 18 and older
- speak fluent English
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.